A new system that delivers Brineura (cerliponase alfa) into the brains of people with CLN2 disease, also known as…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Sex-specific differences in sleep disturbances have been discovered in a mouse model of juvenile Batten disease, according to the…
Drinking acidified laboratory water improved motor performance, restored muscle strength, prevented tremors, and extended survival in a mouse model of…
Researchers have developed a mouse model of juvenile Batten disease that better reflects the survival outcomes of human patients,…
Gene therapy was able to reduce the signs and symptoms of late infantile Batten disease in a mouse model…
Changes in the levels of certain metabolites in the brain among people with juvenile Batten disease, also called CLN3…
A lack of the CLN3 protein — the underlying cause of juvenile Batten disease — impairs the function of…
Regenxbio says it will test RGX-381, its investigational gene therapy for eye problems associated with neuronal ceroid lipofuscinosis…
Neurogene has decided to discontinue its research program focusing on CLN7, a form of late-infantile Batten disease, including…
Researchers have proposed an alternate classification model for Batten disease types based on the site first affected by each…